TumCCA Cancer Research Results

TumCCA, Tumor cell cycle arrest: Click to Expand ⟱
Source:
Type:
Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases. S, G1, G2, and M are the four phases of mitosis.
Scientific Papers found: Click to Expand⟱
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3297- SIL,  Rad,    Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells
- in-vitro, CRC, HCT15 - in-vitro, CRC, RKO
TumCP↓, RadioS↑, TumCCA↑, DNAdam↓, MMP↓, ROS↓, *radioP↑,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1316- SIL,  Chemo,    Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity
- Analysis, Var, NA
TumCCA↑, p42↓, P450↓, OATPs↓, chemoP↑, ChemoSen↑,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
2198- SK,    Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis
- in-vitro, OS, MG63 - in-vitro, OS, 143B
TumCP↓, TumCCA↑, Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, mtDam↑, NRF2↓, xCT↓, GPx4↓, GSH/GSSG↓, Keap1↑,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2229- SK,    Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways
- in-vitro, Melanoma, A375
Apoptosis↑, TumAuto↑, TumCP↓, TumCCA↑, P21↑, cycD1/CCND1↓, ER Stress↑, p‑eIF2α↑, CHOP↑, cl‑Casp3↑, p38↑, LC3B-II↑, Beclin-1↑, ROS↑, eff↓,
2227- SK,    Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, GES-1
selectivity↑, TumCP↓, TumCD↑, ROS↑, MMP↓, Casp↑, Cyt‑c↑, Endon↑, AIF↑, eff↓, ChemoSen↑, TumCCA↑, GSH/GSSG↓, lipid-P↑,
3044- SK,    Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1/CCND1↓, cycE/CCNE↓,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,
3040- SK,    Pharmacological Properties of Shikonin – A Review of Literature since 2002
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA
*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,
5104- SK,    Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression.
- in-vitro, GC, AGS
TumCP↓, TumCCA↑, P21↑,
1312- SK,    Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
- in-vitro, OS, 143B
ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,
2008- SK,  Cisplatin,    Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
1291- SM,    Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCCA↑, BAX↑, Bcl-2↓,
4891- Sper,    Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms
- Review, Var, NA - Review, AD, NA
TumCCA↑, TumCP↓, TumCG↓, *Inflam↓, *antiOx↑, *neuroP↑, *cognitive↑, *Aβ↓, *mitResp↑, AntiCan↑, TumCD↑, TumAuto↑, *AntiAge↑, LC3B-II↑, ATG5↑, Beclin-1↑, mt-ROS↑, H2O2↑, Apoptosis↑, *ROS↑, ChemoSen↑, MMP↓, Cyt‑c↑,
1062- SSE,    Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
- in-vitro, GBM, LN229 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HDAC↓, TumCP↓, TumCCA↑, Apoptosis↑, Casp3↝, MMP2↓, *BioAv↝,
1002- SSE,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,
4739- SSE,  Chemo,  Rad,    Therapeutic Benefits of Selenium in Hematological Malignancies
- Review, Var, NA
ChemoSen↑, radioP↑, QoL↑, Risk↓, *selenoP↑, TumCP↓, Inflam↓, ChemoSen↑, TumCCA↑, Apoptosis↑, angioG↓, Dose⇅, ROS↑, eff↑, Risk↓, eff∅, CSCs↓, ROS↑,
5081- SSE,    Application Notes and Protocols: Selenite as a Selenium Source in Cell Culture Media Supplementation
- Review, Var, NA
Dose↝, ROS↑, Akt↓, mTOR↓, TumCCA↑, Apoptosis↑,
5109- SSE,    Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells
- in-vitro, CRC, HCT116
ROS↑, DNAdam↓, ATM↑, eff↓, TumCCA↑,
5089- SSE,  Se,    Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line
- in-vitro, Pca, LNCaP
ROS↑, mtDam↑, TumCD↑, Apoptosis↑, TumCCA↑, Trx↓, angioG↓, GSH⇅, NADPH↓, GPx↑,
6431- T4O,    Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo
- vitro+vivo, NSCLC, A549
TumCCA↑, Casp3↑, Casp9↑, cl‑PARP↑, MMP↓, Bax:Bcl2↑, XIAP↓, survivin↓, Dose↝, Apoptosis↑, tumCV↓, Cyt‑c↑, eff↑, necrosis↑,
6436- T4O,    Terpinen-4-ol suppresses proliferation and motility of cutaneous squamous cell carcinoma cells by enhancing calpain-2 expression
- in-vitro, Melanoma, A431
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, AntiTum↑, cal2↑, cl‑β-catenin/ZEB1↑, cl‑Casp12↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, BAX↑, TumCCA↑, selectivity↑, N-cadherin↓, E-cadherin↑, Ki-67↓, PCNA↑,
5339- TFdiG,    Pre-treated theaflavin-3,3′-digallate has a higher inhibitory effect on the HCT116 cell line
- in-vitro, CRC, HCT116
eff↑, TumCCA↑, Inflam↓, COX2↓, iNOS↓, P53↑, P21↑, cl‑Casp3↑,
5327- TFdiG,    Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells
- in-vitro, Ovarian, A2780S
TumCG↓, selectivity↑, TumCCA↑, Apoptosis↑, P53↑, BAX↑, BAD↑, cl‑Casp3↑, p‑Akt↓, MDM2↓, MMP↓, Cyt‑c↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
5333- TFdiG,    Theaflavin-3,3′-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human Osteosarcoma Cell Lines and Xenografts
- vitro+vivo, OS, MG63
tumCV↓, TumCP↓, TumCCA↑, Iron↑, ROS↑, GSH↓, Fenton↑, Ferroptosis↑, Apoptosis↑, MAPK↑, ERK↑, JNK↑, p38↑, TumCG↓, Dose↝, FTH1↓, GPx4↓,
962- TQ,    Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways
- in-vitro, PC, PANC1 - in-vitro, Nor, hTERT-HPNE - in-vitro, PC, AsPC-1 - in-vitro, PC, Bxpc-3
TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,
2124- TQ,    Thymoquinone: an emerging natural drug with a wide range of medical applications
- Review, Var, NA
hepatoP↑, Bax:Bcl2↑, cycD1/CCND1↓, P21↑, TRAIL↑, P53↑, TumCCA↑, hepatoP↑, *ALAT↓, *AST↓, *MDA↓, *GSSG↓, *COX2↓, *lipid-P↓, PPARγ↑, p38↑, ROS↑, ChemoSen↑, selectivity↑, selectivity↑, *MDA↓, *SOD↑,
2122- TQ,    Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer
- Review, Var, NA
ChemoSen↓, *ROS↓, *GSH↑, RenoP↑, hepatoP↑, COX2↓, NF-kB↓, chemoPv↑, neuroP↑, TumCCA↑, P21↑, p27↑, ROS↑, DNAdam↑, MUC4↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2129- TQ,  doxoR,    Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
- in-vitro, BC, MCF7
ChemoSen↑, PTEN↑, p‑Akt↓, TumCCA↑, P53↑, P21↑, Apoptosis↑, MMP↓, Casp↑, cl‑PARP↑, Bax:Bcl2↑, eff↓, DNAdam↓, p‑γH2AX↑, ROS↑,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
2095- TQ,    Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis
- Review, Var, NA
TumCCA↑, Apoptosis↑, ROS↑, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, cl‑PARP↑, P53↑, P21↑, cMyc↓, hTERT/TERT↓, cycD1/CCND1↓, CDK4↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, eff↑,
2105- TQ,    Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation
- in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, Hs766t - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, P53↑, Bcl-2↓, P21↑, ac‑H4↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, TumVol↓,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,
2108- TQ,    Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa
- Review, Var, NA
HDAC↓, TumCCA↑, cycD1/CCND1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, survivin↓, COX2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,
1930- TQ,    Therapeutic implications and clinical manifestations of thymoquinone
- Review, Var, NA
AntiCan↑, antiOx↑, Inflam↓, TumCP↓, TumCCA↑, Apoptosis↑, ROS↑, TumMeta↓, TumCI↓,
1931- TQ,  doxoR,    Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms
- in-vivo, AML, NA
eff↑, tumCV↓, TumCCA↑, ROS↑, MMP↓, eff↑, TumVol↓, eff↑, Ki-67↓,
1933- TQ,    Thymoquinone: potential cure for inflammatory disorders and cancer
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCCA↑, ROS↑, angioG↓, Apoptosis↑, Casp↑, eff↑, eff↝,

Showing Research Papers: 751 to 800 of 837
Prev Page 16 of 17 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 837

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   CYP1A1↓, 1,   Fenton↑, 1,   Ferroptosis↑, 3,   GPx↑, 1,   GPx4↓, 2,   GSH↓, 4,   GSH⇅, 1,   GSH/GSSG↓, 2,   H2O2↑, 1,   Iron↑, 2,   Keap1↑, 1,   lipid-P↑, 2,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 3,   ROS↑, 32,   ROS⇅, 2,   i-ROS↑, 1,   mt-ROS↑, 1,   SOD↓, 1,   SOD1↓, 1,   SOD2↓, 1,   Trx↓, 1,   xCT↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   MEK↓, 1,   MMP↓, 14,   mtDam↑, 2,   p42↓, 1,   Raf↓, 1,   XIAP↓, 6,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 5,   LDH↝, 1,   NADPH↓, 1,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 2,   PPARγ↑, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 6,   p‑Akt↓, 6,   Apoptosis↓, 1,   Apoptosis↑, 28,   BAD↑, 1,   BAX↑, 8,   Bax:Bcl2↑, 5,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 6,   BID↑, 1,   BIM↑, 1,   Casp↑, 6,   cl‑Casp12↑, 1,   Casp3↑, 9,   Casp3↝, 1,   cl‑Casp3↑, 6,   proCasp3↓, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 6,   cl‑Casp9↑, 1,   Cyt‑c↑, 10,   Endon↑, 1,   Ferroptosis↑, 3,   hTERT/TERT↓, 2,   IAP1↓, 3,   IAP2↓, 2,   IAP2↑, 1,   iNOS↓, 2,   JNK↑, 2,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 1,   MAPK↑, 2,   Mcl-1↓, 4,   MDM2↓, 1,   Necroptosis↑, 1,   necrosis↑, 1,   NOXA↑, 1,   p27↑, 3,   p38↑, 3,   p‑p38↓, 1,   p‑p38↑, 1,   survivin↓, 9,   Telomerase↓, 2,   TRAIL↑, 1,   TumCD↑, 4,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,   HER2/EBBR2↓, 1,   p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H4↑, 1,   HATs↑, 1,   miR-21↓, 1,   p‑pRB↓, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 1,   eIF2α↓, 1,   p‑eIF2α↑, 2,   ER Stress↑, 2,   HSP70/HSPA5↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   LC3B-II↑, 2,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   DNAdam↓, 3,   DNAdam↑, 4,   DNMT1↓, 2,   p16↑, 1,   P53↑, 16,   cl‑PARP↑, 12,   PCNA↓, 3,   PCNA↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 4,   CDK4↓, 6,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 14,   cycE/CCNE↓, 3,   E2Fs↓, 1,   P21↑, 10,   RB1↑, 1,   TumCCA↓, 2,   TumCCA↑, 48,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   CD44↓, 1,   CSCs↓, 2,   EMT↓, 5,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 2,   p‑ERK↑, 1,   GSK‐3β↑, 1,   HDAC↓, 4,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   IGFBP3↑, 1,   miR-34a↑, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   NOTCH↓, 2,   NOTCH1↓, 1,   PI3K↓, 7,   PI3K↑, 1,   PTEN↑, 3,   RAS↓, 1,   Src↑, 1,   STAT3↓, 5,   p‑STAT3↓, 3,   STAT5↓, 1,   TumCG↓, 8,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Akt2↓, 1,   AP-1↓, 1,   CA↓, 1,   Ca+2↑, 1,   cal2↑, 1,   E-cadherin↑, 4,   FAK↓, 1,   Ki-67↓, 3,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 6,   MMP9↓, 6,   MUC4↓, 2,   N-cadherin↓, 3,   PDGF↓, 1,   Rac1↓, 1,   Slug↓, 1,   Snail↓, 1,   TET1↑, 1,   TGF-β↓, 2,   TumCI↓, 5,   TumCMig↓, 7,   TumCP↓, 19,   TumMeta↓, 4,   Twist↓, 1,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 2,   α-SMA↓, 1,   α-tubulin↓, 1,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   EGFR↓, 4,   p‑EGFR↓, 3,   HIF-1↓, 1,   Hif1a↓, 7,   KDR/FLK-1↓, 1,   LOX1↓, 1,   VEGF↓, 8,  

Barriers & Transport(tgid=15) ⓘ

NHE1↓, 1,   OATPs↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 10,   CXCR4↓, 3,   IFN-γ↓, 1,   IL1↓, 2,   IL1β↓, 2,   IL6↓, 3,   Inflam↓, 9,   IκB↓, 1,   JAK1?, 1,   p‑JAK1↓, 1,   JAK2↓, 2,   p‑JAK2↓, 1,   NF-kB↓, 12,   NK cell↑, 1,   p65↓, 1,   p‑p65↓, 1,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 3,   TNF-α↓, 2,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 7,   BioAv↑, 3,   ChemoSen↓, 1,   ChemoSen↑, 12,   Dose↑, 1,   Dose⇅, 1,   Dose↝, 6,   eff↓, 8,   eff↑, 15,   eff↝, 2,   eff∅, 1,   Half-Life↓, 1,   Half-Life↝, 3,   P450↓, 1,   RadioS↑, 4,   selectivity↑, 10,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   EGFR↓, 4,   p‑EGFR↓, 3,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 3,   Ki-67↓, 3,   LDH↝, 1,   PD-L1↓, 2,   PSA↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 6,   AntiTum↑, 2,   cardioP↑, 2,   chemoP↑, 6,   chemoPv↑, 2,   hepatoP↑, 6,   neuroP↑, 1,   QoL↑, 1,   radioP↑, 3,   RenoP↑, 1,   Risk↓, 2,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 4,  
Total Targets: 266

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 1,   GSSG↓, 1,   GSTA1↓, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 3,   MDA↓, 2,   MPO↓, 1,   ROS↓, 5,   ROS↑, 1,   selenoP↑, 1,   SOD↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Bcl-2↑, 1,   JNK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

STAT3↑, 1,  

Migration(tgid=13) ⓘ

TIMP1↓, 1,   TumCI∅, 1,   TumCMig∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL8↓, 1,   Inflam↓, 3,   NF-kB↑, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

GR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 2,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   neuroP↑, 2,   radioP↑, 1,   toxicity↓, 3,  
Total Targets: 46

Scientific Paper Hit Count for: TumCCA, Tumor cell cycle arrest
41 Curcumin
31 Quercetin
29 Silver-NanoParticles
25 Thymoquinone
25 Sulforaphane (mainly Broccoli)
22 Apigenin (mainly Parsley)
22 Berberine
17 Phenethyl isothiocyanate
16 Baicalein
15 Artemisinin
15 Capsaicin
15 Fisetin
15 Piperlongumine
14 Shikonin
13 Radiotherapy/Radiation
13 EGCG (Epigallocatechin Gallate)
13 Chrysin
13 Emodin
12 Magnetic Fields
12 Ashwagandha(Withaferin A)
12 Betulinic acid
12 Eugenol
12 Cucurbitacin
12 Resveratrol
11 Magnolol
11 Lycopene
10 Propolis -bee glue
10 Garcinol
10 Honokiol
9 Cisplatin
9 Rosmarinic acid
9 Ellagic acid
9 Graviola
9 Silymarin (Milk Thistle) silibinin
9 Urolithin
8 Allicin (mainly Garlic)
8 Carvacrol
8 Crocetin
8 Luteolin
7 Chemotherapy
7 chitosan
7 Phenylbutyrate
7 Pterostilbene
6 5-fluorouracil
6 doxorubicin
6 Astaxanthin
6 Berbamine
6 Boswellia (frankincense)
6 Celastrol
6 Naringin
6 Selenite (Sodium)
5 Coenzyme Q10
5 Beta-Caryophyllene
5 Bufalin/Huachansu
5 Boron
5 Caffeic Acid Phenethyl Ester (CAPE)
5 Centella asiatica / Gotu kola → asiaticoside
5 Chlorogenic acid
5 Carvone
5 Dandelion Root
5 Eurycomanone
5 Paclitaxel
5 Nimbolide
5 Plumbagin
5 salinomycin
5 Ursolic acid
5 Vitamin K2
4 1,8-Cineole
4 Vitamin C (Ascorbic Acid)
4 D-limonene
4 Brucea javanica
4 Caffeic acid
4 Thymol-Thymus vulgaris
4 Selenium
4 Cinnamon
4 Hydroxycinnamic-acid
4 Deguelin
4 HydroxyTyrosol
4 Juglone
4 Laetrile B17 Amygdalin
4 Linalool
4 VitK3,menadione
4 α-Santalol/Sandalwood oil
4 Selenium NanoParticles
4 Aflavin-3,3′-digallate
3 Astragalus
3 Copper and Cu NanoParticles
3 Alpha-Lipoic-Acid
3 Andrographis
3 Gemcitabine (Gemzar)
3 Anethole/trans-Anethole
3 Fennel Oil/Foeniculum vulgare
3 Biochanin A
3 borneol
3 Bruteridin(bergamot juice)
3 Carnosic acid
3 Celecoxib
3 Date Fruit Extract
3 Piperine
3 Ferulic acid
3 Gallic acid
3 Gambogic Acid
3 Genistein (soy isoflavone)
3 Metformin
3 Magnetic Field Rotating
3 Propyl gallate
3 Parthenolide
2 tamoxifen
2 Glucose
2 Gold NanoParticles
2 Photodynamic Therapy
2 DTS(dibenzyl trisulphide) from Anamu
2 Ascorbyl Palmitate
2 Melatonin
2 Atorvastatin
2 beta-glucans
2 Baicalin
2 Bacopa monnieri
2 α-Bisabolol / Chamomile oil
2 Butyrate
2 Zinc
2 Chlorophyllin
2 Dihydrocaffeic Acid
2 Cyclopamine
2 Dichloroacetate
2 Diclofenac
2 diet Methionine-Restricted Diet
2 Echinacea
2 Electrical Pulses
2 carboplatin
2 Geraniol
2 Hyperthermia
2 itraconazole
2 Licorice
2 Methylene blue
2 Magnesium
2 Oleuropein
2 Terpinen-4-ol / Tea Tree Oil
1 Ajoene (compound of Garlic)
1 alpha Linolenic acid
1 Arctigenin
1 Aloe anthraquinones
1 immunotherapy
1 epirubicin
1 brusatol
1 Bromelain
1 Carnosine
1 Selenate
1 Docetaxel
1 Chocolate
1 Vitamin E
1 Docosahexaenoic Acid
1 diet FMD Fasting Mimicking Diet
1 Dipyridamole
1 Disulfiram
1 Cannabichromene
1 Evodiamine
1 Citric Acid
1 Sorafenib (brand name Nexavar)
1 Fenbendazole
1 Shilajit/Fulvic Acid
1 Galloflavin
1 Rapamycin
1 Inositol
1 Methylglyoxal
1 Methylsulfonylmethane
1 Mushroom Chaga
1 Myricetin
1 Niclosamide (Niclocide)
1 Proanthocyanidins
1 Sanguinarine
1 Psoralidin
1 Kaempferol
1 Rutin
1 Oxaliplatin
1 Sulfasalazine
1 Auranofin
1 Salvia miltiorrhiza
1 Spermidine
1 Osimertinib
1 Adagrasib
1 Turmerones
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:322  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page